Whittier Trust Co. of Nevada Inc. Has $1.33 Million Holdings in Becton Dickinson and Co (NYSE:BDX)

Whittier Trust Co. of Nevada Inc. boosted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 8.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,251 shares of the medical instruments supplier’s stock after buying an additional 391 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Becton Dickinson and were worth $1,328,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its holdings in shares of Becton Dickinson and by 0.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 34,250,739 shares of the medical instruments supplier’s stock valued at $8,631,529,000 after purchasing an additional 131,536 shares during the period. Vanguard Group Inc. boosted its position in Becton Dickinson and by 2.3% during the second quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock worth $5,800,769,000 after purchasing an additional 520,350 shares during the period. Morgan Stanley boosted its position in Becton Dickinson and by 66.7% during the second quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock worth $1,231,621,000 after purchasing an additional 1,955,095 shares during the period. Northern Trust Corp boosted its position in Becton Dickinson and by 1.5% during the second quarter. Northern Trust Corp now owns 3,271,013 shares of the medical instruments supplier’s stock worth $824,327,000 after purchasing an additional 47,202 shares during the period. Finally, Bank of America Corp DE boosted its position in Becton Dickinson and by 4.1% during the second quarter. Bank of America Corp DE now owns 2,901,319 shares of the medical instruments supplier’s stock worth $731,162,000 after purchasing an additional 114,398 shares during the period. Hedge funds and other institutional investors own 84.26% of the company’s stock.

In other Becton Dickinson and news, Director Claire Fraser sold 1,429 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $243.26, for a total transaction of $347,618.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Charles R. Bodner sold 1,514 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.08, for a total value of $393,761.12. Following the transaction, the senior vice president now owns 5,180 shares of the company’s stock, valued at $1,347,214.40. The disclosure for this sale can be found here. Insiders have sold 37,249 shares of company stock valued at $9,616,803 over the last quarter. Corporate insiders own 0.12% of the company’s stock.

A number of brokerages have issued reports on BDX. Piper Jaffray Companies decreased their target price on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Raymond James increased their price objective on Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research report on Friday, June 28th. ValuEngine cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Wells Fargo & Co increased their price objective on Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a research report on Friday, September 6th. Finally, Morgan Stanley increased their price objective on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 16th. Five equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $266.55.

Shares of NYSE BDX opened at $255.86 on Monday. The business has a fifty day simple moving average of $254.23 and a 200 day simple moving average of $246.15. The company has a current ratio of 1.09, a quick ratio of 0.67 and a debt-to-equity ratio of 0.84. The firm has a market capitalization of $69.32 billion, a price-to-earnings ratio of 23.24, a PEG ratio of 1.64 and a beta of 1.12. Becton Dickinson and Co has a one year low of $208.62 and a one year high of $264.74.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 EPS for the quarter, beating analysts’ consensus estimates of $3.05 by $0.03. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The business had revenue of $4.35 billion during the quarter, compared to analyst estimates of $4.37 billion. During the same period in the prior year, the company posted $2.91 earnings per share. Becton Dickinson and’s revenue was up 1.7% on a year-over-year basis. On average, research analysts anticipate that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: What is an economic bubble?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.